Stock CDT CONDUIT PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Conduit Pharmaceuticals Inc.

Equities

CDT

US20678X1063

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
2.86 USD -3.38% Intraday chart for Conduit Pharmaceuticals Inc. -5.61% -37.14%
May. 14 Conduit Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 19 Conduit Pharmaceuticals Inc. Appoints Joanne Holland as Chief Scientific Officer CI

Business Summary

Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis (HT and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).

Number of employees: 7

Managers

Managers TitleAgeSince
David Tapolczay CEO
 Chief Executive Officer 64 23-09-21
Adam Sragovicz DFI
 Director of Finance/CFO 55 21-09-30

Members of the board

Members of the board TitleAgeSince
Freda Lewis-Hall CHM
 Chairman 69 23-09-21
Jennifer McNealey BRD
 Director/Board Member 50 23-09-21
Faith Charles BRD
 Director/Board Member 62 23-09-21
Andrew Regan BRD
 Director/Board Member 59 23-09-21
David Tapolczay CEO
 Chief Executive Officer 64 23-09-21
Chele Farley BRD
 Director/Board Member 56 23-09-21
James Bligh BRD
 Director/Board Member 36 23-09-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 73,829,536 9,928,091 ( 13.45 %) 0 13.45 %

Shareholders

NameEquities%Valuation
Corvus Capital Ltd. (Cayman Islands)
61.67 %
45,527,149 61.67 % 141 M $
St George Street Capital Ltd.
6.433 %
4,749,816 6.433 % 15 M $
Nirland Ltd.
6.123 %
4,520,311 6.123 % 14 M $
Murphy Canyon Acquisition Sponsor LLC
5.439 %
4,015,250 5.439 % 12 M $
Freda Lewis-Hall
3.414 %
2,520,311 3.414 % 8 M $
David Tapolczay
2.713 %
2,003,324 2.713 % 6 M $
Barclays Bank Plc
1.089 %
804,292 1.089 % 2 M $
James Bligh
0.3029 %
223,634 0.3029 % 693 265 $
Vanguard Global Advisers LLC
0.2816 %
207,892 0.2816 % 644 465 $
BlackRock Institutional Trust Co. NA
0.2077 %
153,355 0.2077 % 475 401 $
NameEquities%Valuation
Highbridge Capital Management LLC
-
1,448,217 - 115 857 $
Polar Asset Management Partners, Inc.
-
950,000 - 76 000 $
Saba Capital Management LP
-
765,000 - 61 200 $
MMCAP International Inc. SPC
-
700,000 - 56 000 $
Exos Asset Management LLC
-
554,746 - 44 380 $
Walleye Capital LLC
-
516,032 - 41 283 $
Clear Street LLC
-
410,032 - 32 803 $
D.E. Shaw & Co., Inc.
-
375,000 - 30 000 $
EHP Funds, Inc.
-
300,622 - 24 050 $
EdgeHill Partners
-
300,622 - 24 050 $

Company contact information

Conduit Pharmaceuticals, Inc.

4995 Murphy Canyon Road Suite 300

92123, San Diego

+

http://www.conduitpharma.com
address Conduit Pharmaceuticals Inc.(CDT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CONDUIT PHARMACEUTICALS INC. Stock Conduit Pharmaceuticals Inc.
-37.14% 219M
MODERNA, INC. Stock Moderna, Inc.
+55.70% 55.7B
LONZA GROUP AG Stock Lonza Group AG
+41.08% 39.91B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.39% 39.57B
CELLTRION, INC. Stock Celltrion, Inc.
-5.56% 28.16B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+16.46% 26.3B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.56% 18.94B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+33.03% 12.17B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.85% 12.12B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.72% 12.12B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CDT Stock
  4. Company Conduit Pharmaceuticals Inc.